% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Millstein:156955,
author = {J. Millstein and T. Budden and E. L. Goode and M. S.
Anglesio and A. Talhouk and M. P. Intermaggio and H. S.
Leong and S. Chen and W. Elatre and B. Gilks and T. Nazeran
and M. Volchek and R. C. Bentley and C. Wang and D. S. Chiu
and S. Kommoss and S. C. Y. Leung and J. Senz and A. Lum and
V. Chow and H. Sudderuddin and R. Mackenzie and J. George
and S. Fereday and J. Hendley and N. Traficante and H. Steed
and J. M. Koziak and M. Köbel and I. A. McNeish and T.
Goranova and D. Ennis and G. Macintyre and D. Silva De Silva
and T. Ramón Y Cajal and J. García-Donas and S. Hernando
Polo and G. C. Rodriguez and K. L. Cushing-Haugen and H. R.
Harris and C. S. Greene and R. A. Zelaya and S. Behrens$^*$
and R. T. Fortner$^*$ and P. Sinn and E. Herpel and J.
Lester and J. Lubiński and O. Oszurek and A. Tołoczko and
C. Cybulski and J. Menkiszak and C. L. Pearce and M. C. Pike
and C. Tseng and J. Alsop and V. Rhenius and H. Song and M.
Jimenez-Linan and A. M. Piskorz and A. Gentry-Maharaj and C.
Karpinskyj and M. Widschwendter and N. Singh and C. J.
Kennedy and R. Sharma and P. R. Harnett and B. Gao and S. E.
Johnatty and R. Sayer and J. Boros and S. J. Winham and G.
L. Keeney and S. H. Kaufmann and M. C. Larson and H. Luk and
B. Y. Hernandez and P. J. Thompson and L. R. Wilkens and M.
E. Carney and B. Trabert and J. Lissowska and L. Brinton and
M. E. Sherman and C. Bodelon and S. Hinsley and L. A.
Lewsley and R. Glasspool and S. N. Banerjee and E. A.
Stronach and P. Haluska and I. Ray-Coquard and S. Mahner and
B. Winterhoff and D. Slamon and D. A. Levine and L. E.
Kelemen and J. Benitez and J. Chang-Claude$^*$ and J.
Gronwald and A. H. Wu and U. Menon and M. T. Goodman and J.
M. Schildkraut and N. Wentzensen and R. Brown and A.
Berchuck and G. Chenevix-Trench and A. deFazio and S. A.
Gayther and M. J. García and M. J. Henderson and M. A.
Rossing and A. Beeghly-Fadiel and P. A. Fasching and S.
Orsulic and B. Y. Karlan and G. E. Konecny and D. G.
Huntsman and D. D. Bowtell and J. D. Brenton and J. A.
Doherty and P. D. P. Pharoah and S. J. Ramus},
collaboration = {A. Group},
title = {{P}rognostic gene expression signature for high-grade
serous ovarian cancer.},
journal = {Annals of oncology},
volume = {31},
number = {9},
issn = {0923-7534},
address = {Oxford},
publisher = {Oxford Univ. Press},
reportid = {DKFZ-2020-01260},
pages = {1240-1250},
year = {2020},
note = {2020 Sep;31(9):1240-1250},
abstract = {Median overall survival (OS) for women with high-grade
serous ovarian cancer (HGSOC) is ∼4 years, yet survival
varies widely between patients. There are no
well-established, gene expression signatures associated with
prognosis. The aim of this study was to develop a robust
prognostic signature for OS in patients with
HGSOC.Expression of 513 genes, selected from a meta-analysis
of 1455 tumours and other candidates, was measured using
NanoString technology from formalin-fixed paraffin-embedded
tumour tissue collected from 3769 women with HGSOC from
multiple studies. Elastic net regularization for survival
analysis was applied to develop a prognostic model for
5-year OS, trained on 2702 tumours from 15 studies and
evaluated on an independent set of 1067 tumours from six
studies.Expression levels of 276 genes were associated with
OS (false discovery rate < 0.05) in covariate-adjusted
single-gene analyses. The top five genes were TAP1, ZFHX4,
CXCL9, FBN1 and PTGER3 (P < 0.001). The best performing
prognostic signature included 101 genes enriched in pathways
with treatment implications. Each gain of one standard
deviation in the gene expression score conferred a greater
than twofold increase in risk of death [hazard ratio (HR)
2.35, $95\%$ confidence interval (CI) 2.02-2.71; P < 0.001].
Median survival [HR $(95\%$ CI)] by gene expression score
quintile was 9.5 (8.3 to -), 5.4 (4.6-7.0), 3.8 (3.3-4.6),
3.2 (2.9-3.7) and 2.3 (2.1-2.6) years.The OTTA-SPOT (Ovarian
Tumor Tissue Analysis consortium - Stratified Prognosis of
Ovarian Tumours) gene expression signature may improve risk
stratification in clinical trials by identifying patients
who are least likely to achieve 5-year survival. The
identified novel genes associated with the outcome may also
yield opportunities for the development of targeted
therapeutic approaches.},
cin = {C020},
ddc = {610},
cid = {I:(DE-He78)C020-20160331},
pnm = {313 - Cancer risk factors and prevention (POF3-313)},
pid = {G:(DE-HGF)POF3-313},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:32473302},
doi = {10.1016/j.annonc.2020.05.019},
url = {https://inrepo02.dkfz.de/record/156955},
}